Combining Free Fatty Acids With NT-proBNP Peptide Biomarker Improves Heart Failure Risk Prediction | Research

The takeaway

In 4,109 heart failure patients followed up to 8 years, elevated free fatty acids independently predicted cardiovascular death and hospitalization, and combining FFA with the natriuretic peptide biomarker NT-proBNP significantly improved risk stratification.

HR 1.45 for CV death
Patients with the highest free fatty acid levels had 45% greater cardiovascular death risk, and adding FFA to NT-proBNP significantly improved prediction beyond the peptide biomarker alone

What the researchers found

Among 4,109 HF patients (median follow-up 25 months, max 8 years), FFA levels above 0.4-0.42 mmol/L were associated with increased risk of all three outcomes. Patients in the highest FFA tertile had significantly elevated risks versus the lowest tertile:

- CV death & HF hospitalization: HR 1.32 (95% CI: 1.11-1.58)

- CV death alone: HR 1.45 (95% CI: 1.16-1.82)

- All-cause mortality: HR 1.39 (95% CI: 1.15-1.68)

These associations were consistent across HF subtypes (HFpEF and HFmrEF/HFrEF). Combining FFA with the natriuretic peptide biomarker NT-proBNP significantly improved the C-index for predicting outcomes compared to NT-proBNP alone (P < 0.01).

Why it matters

NT-proBNP is the most widely used peptide biomarker in cardiology, but its predictive power has limitations. This study shows that adding a simple, inexpensive metabolic marker (FFA) to NT-proBNP significantly improves risk stratification in heart failure. For peptide biomarker science, this demonstrates that natriuretic peptides work best as part of multi-marker panels rather than in isolation.

How the study worked

Prospective cohort study of 4,109 heart failure patients. Plasma FFA was analyzed as continuous and categorical (tertiles) variables. Cox regression models assessed associations with three outcomes: composite CV death and HF hospitalization, CV death alone, and all-cause mortality. Subgroup analyses by ejection fraction. C-index calculated for the combination of FFA and NT-proBNP versus NT-proBNP alone.

What this study cannot tell us

This is an observational cohort study and cannot establish causation between elevated FFA and worse outcomes. The study population was from a single center, which may limit generalizability. FFA levels were measured at a single timepoint and may fluctuate with fasting status, diet, and medications. The study did not assess whether lowering FFA levels (e.g., through GLP-1 agonist treatment) improves outcomes.

How to read the evidence

This is a large (n=4,109) prospective cohort study with long follow-up (up to 8 years). The use of Cox regression with adjustment for confounders, consistent results across HF subtypes, and quantitative improvement in C-index provide strong observational evidence for the FFA + NT-proBNP combination.

When this study was published

Published in 2024, this study provides contemporary evidence for multi-biomarker approaches in heart failure risk stratification.

The bigger picture

This study contributes to the evolution of cardiac biomarker panels. While NT-proBNP remains the cornerstone natriuretic peptide biomarker, combining it with metabolic markers like FFA creates a more comprehensive risk picture. This multi-biomarker approach — where peptide markers provide cardiac-specific information and metabolic markers add systemic context — likely represents the future of heart failure risk assessment.

Questions still open

Would interventions that lower free fatty acids (weight loss, GLP-1 agonists, metabolic therapies) improve heart failure outcomes?
Should clinical guidelines recommend routine FFA measurement alongside NT-proBNP in heart failure management?
Does the FFA + NT-proBNP combination outperform other emerging cardiac biomarker panels?

Common questions

What is NT-proBNP and why is it important?

NT-proBNP is a fragment of the natriuretic peptide BNP, released by the heart when it's under stress. It's the gold standard blood test for diagnosing and monitoring heart failure. This study shows that combining it with free fatty acid measurements makes it even more powerful at predicting which patients are at highest risk.

What do high free fatty acids mean for heart failure patients?

Elevated free fatty acids in the blood indicate metabolic stress and are linked to insulin resistance and lipotoxicity — conditions that can worsen heart function. This study found that HF patients with FFA above 0.4 mmol/L had significantly higher risks of cardiovascular death and hospitalization, independent of other risk factors.

Read the original research

Free fatty acids: independent predictors of long-term adverse cardiovascular outcomes in heart failure patients.

Lipids in health and disease, 23(1), 343

View on PubMed ↗Publisher’s paper ↗

Citation

Liao, Guang-Zhi; Liu, Hui-Hui; He, Chun-Hui; Feng, Jia-Yu; Zhuang, Xiao-Feng; Wang, Jing-Xi; Zhou, Ping; Huang, Yan; Zhou, Qiong; Zhai, Mei; Zhang, Yu-Hui; Zhang, Jian. (2024). Free fatty acids: independent predictors of long-term adverse cardiovascular outcomes in heart failure patients.. Lipids in health and disease, 23(1), 343. https://doi.org/10.1186/s12944-024-02332-5